医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Exscientia to Present at Upcoming Investor Conferences in November

2022年11月01日 PM09:00
このエントリーをはてなブックマークに追加


 

OXFORD, England

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November:

  • BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, at 12:40 p.m. EST (5:40 p.m. GMT)
  • 2022 Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 16, 2022, in London, United Kingdom
  • 5th Annual Evercore ISI HealthCONx Conference. Fireside chat on Tuesday, November 29, 2022, at 8:50 a.m. EST (1:50 p.m. GMT)

Live webcasts of the fireside chats will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005278/en/

CONTACT

Investors:

Sara Sherman

investors@exscientia.ai

Media:

media@exscientia.ai

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • メアリー・ケイ、米国栄養学会の年次総会で植物葉エキスの効能に関する新たな研究結果を発表
  • ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
  • PHCの遠隔医療システム「Teladoc HEALTH」がシェアメディカルのデジタル聴診デバイス「ネクステート」と接続 ~ 接続機器の拡充により遠隔聴診を実現 ~
  • Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI
  • Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI